Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mesoblast Limited ( (AU:MSB) ) just unveiled an announcement.
Mesoblast has disclosed changes in the securities held by director Dr Eric Rose, who has adjusted his shareholding through the exercise of options and associated on-market trades. Between 6 and 9 January 2026, Rose exercised options approved at the company’s 2024 annual meeting, acquiring 1,280,651 ordinary shares and selling 638,670 shares on-market to fund the option exercise price and associated tax liabilities, resulting in a net increase in his direct holding to 6,749,274 ordinary shares and a reduction of his option holdings to 5,593,451. The transaction, conducted to avoid the expiry of options due in March 2026, signals continued equity alignment between the director and shareholders and reflects standard capital management and remuneration-related activity rather than a change in company strategy or operations.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is an Australian biotechnology company focused on developing and commercializing cellular medicines, particularly allogeneic, off-the-shelf regenerative therapies. Its primary products and pipeline candidates target inflammatory diseases, cardiovascular conditions, and musculoskeletal disorders, with a strategic emphasis on large-market indications where cell-based therapies could offer advantages over existing treatments.
Average Trading Volume: 4,197,680
Technical Sentiment Signal: Buy
Current Market Cap: A$3.94B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.